The European Commission Digital Agenda aim to shape a Europe fit for the digital age. Health is one of the key areas that needs to be digitalised for patients, healthcare providers and healthcare systems benefits.

Medicines for Europe believes that in this context the regulatory systems can have a pivotal role. As in the Pharmaceutical Strategy, there is a need to make the lifecycle management of medicines more efficient and adapted to digitalisation.

Member States continue to conduct evaluations of their 2014-2020 EU Structural and Cohesion Funds projects and programmes. Have they collected the best monitoring data and do they know how to measure impacts? Which evaluation method should be used – theory-based or counter-factual? As new programmes for 2021-2027 are now being agreed and implemented, are we clear about what the New Regulations say about monitoring and evaluation requirements?

This is a webinar over 5 days (mornings and afternoons):